Tyra Biosciences stock reaction

Tyra Biosciences (TYRA) has drawn attention after recent trading, with the stock closing at US$25.42 and showing sizeable swings over the past month and past 3 months. This has prompted fresh questions about how investors view this clinical-stage biotech.

Recent momentum has cooled, with the share price down 11.4% over the past week and 25.3% over the past month. However, the 1 year total shareholder return of 149.7% still points to a much stronger longer run outcome.

If Tyra’s swings have your attention, it can be useful to see how other high growth areas are moving by scanning 39 healthcare AI stocks

With Tyra Biosciences still loss making, showing very strong 1 year returns and trading at a market value of about US$1.5b, the key question is whether recent weakness creates a buying opportunity or if the market is already pricing in future growth.

Preferred Price-to-Book of 3.9x: Is it justified?

Tyra Biosciences currently trades on a P/B of 3.9x, which screens as expensive against the broader US Biotechs industry but cheaper than a peer group average.

The P/B ratio compares the stock price with the company’s book value, which is its net assets on the balance sheet. For early stage biotech companies that are still loss making and have limited revenue, investors often lean on P/B because earnings based metrics like P/E are not yet meaningful.

For Tyra, the current P/B of 3.9x sits above the US Biotechs industry average of 2.4x, so the stock is priced at a premium compared to the typical listed biotech. At the same time, it trades at a discount to a closer peer set where the average P/B is 6.1x, so the market is valuing Tyra’s balance sheet more conservatively than some of its nearer comparables.

Result: Price-to-book of 3.9x (ABOUT RIGHT)

However, the story can change quickly if clinical trial results disappoint or if ongoing losses of US$131.105m begin to weigh more heavily on sentiment toward the stock.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

With sentiment clearly mixed, this is a moment to look at the numbers yourself and decide quickly where you stand. Start with the 2 key rewards and 3 important warning signs.

Looking for more investment ideas?

If Tyra has sharpened your interest, do not stop here. Use the Simply Wall Street Screener to surface other focused opportunities that could suit your approach.

• Target stability seekers by reviewing 63 resilient stocks with low risk scores that score well on resilience while keeping downside risk in check.
• Hunt for value by scanning 47 high quality undervalued stocks that pair solid fundamentals with what could be appealing pricing.
• Strengthen your income watchlist by assessing 9 dividend fortresses that aim to combine higher yields with balance sheet support.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.